Project description:We collected cells at three key stages of human iPSC-derived cardiomyocytes (day 0, day 8, and day 15), and performed proteomic and ubiquitinomic analysis.
Project description:To investigate gene regulatory dynamics of normal endothelial cell (EC) differentiation at high resolution, an in vitro differentiation system was employed to derive functional vascular ECs from human embryonic stem cells. Human embryonic stem cells, mesodermal cells, and differentiating cells following VEGF-A stimulation at eight time points (1–48 hours), along with internal controls without VEGF-A treatment (referred to as non-ECs), were collected to profile global RNA expression and H3K27ac signals. In addition, in situ Hi-C data were generated for ECs and non-ECs at 24 hours after VEGF-A treatment to characterize global chromatin contact profiles associated with the EC progenitor state.
Project description:The de novo generation of human hematopoietic stem cells (HSCs) from induced pluripotent stem cells (iPSCs) represents a promising avenue for the cellular therapy of blood disorders. However, existing protocols often result in the production of immature progenitors with limited multilineage engraftment capacity in vivo. This limitation is believed to be due to an epigenetic barrier, particularly involving the Polycomb Repressor Complex 2 (PRC2), which mediates transcriptional repression during hematopoietic development through H3K27me3 methylation. In this study, we explored the suppression of EZH2, a key component of PRC2, using the small molecule inhibitor GSK126 at various stages of iPSC differentiation. Our findings revealed that EZH2 inhibition leads to an increase in phenotypic HSCs and enhances long-term colony-forming unit (CFU) colony formation. Single-cell RNA sequencing further demonstrated that GSK126 promotes iPSC hematopoietic differentiation. These results highlight the potential of EZH2 inhibition to overcome epigenetic barriers and enhance iPSC-derived hematopoietic differentiation, paving the way for advancements in regenerative medicine and transplantation therapies.